AI to predict cancer return after liver surgery
Part of Cancer clinical trials.
This trial uses artificial intelligence to predict whether colorectal cancer that spread to the liver will come back after surgery. It may help doctors better understand your risk and plan follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove liver tumors that started from colon or rectal cancer.
- Your cancer was confirmed as adenocarcinoma (a common type of colorectal cancer).
- You have been followed for at least 6 months after surgery.
- You do not have another type of cancer at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses an AI tool to predict how liver cancer might come back after surgery. It is for people with early-stage liver cancer who are already scheduled for surgery and have recent MRI scans.
This study tests whether an artificial intelligence (AI) model can predict if colon or rectal cancer will spread to the liver. You will have a CT scan before surgery, and the AI will analyze the scan to see if it can forecast future liver metastasis.
This study looks at whether an AI tool can predict if colorectal cancer will spread to the liver. The researchers will review past medical records of patients who had surgery to remove their cancer and had no signs of spread at that time.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
This trial tests whether an artificial intelligence system can help detect liver cancer recurrence earlier after curative treatment, allowing for potentially curative salvage therapy. Participants who have undergone complete surgical removal or ablation of their first liver cancer will be monitored with AI-assisted imaging.
This study uses artificial intelligence to analyze imaging and tumor data from patients with hepatocellular carcinoma (liver cancer) being treated with a combination of TACE (a minimally invasive procedure), immunotherapy, and targeted therapy. The goal is to better predict which patients will respond well to treatment.
Hear when a new Colorectal Liver Metastasis (CRLM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.